Gastrointestinal Oncology, 1998 Cancer Treatment and Research Series, Vol. 98

Gastrointestinal tract malignancies encompass a spectrum of diseases with marked differences in etiology, incidence, biological behavior, and treatment outcome. The incidence of new gastrointestinal cases recorded yearly for patients residing in the United States is approximately 230,000, representing nearly 20% of all cancer cases. Worldwide, gastrointestinal malignancies are responsible for the largest number of cancer deaths, particularly because of the high incidence of hepatocellular and gastric cancer in other countries.
Gastrointestinal Oncology is directed to those most involved in the multidisciplinary approach to the gastrointestinal cancer patient, including medical, radiation and surgical oncologists; gastroenterologists; interventional radiologists; pathologists; oncology nurses; and oncology physicians-in-training.

1. Esophageal Cancer.- 2. Adjuvant Chemotherapy in Gastric Adenocarcinomas.- 3. Management of Exocrine Carcinomas of the Pancreas.- 4. Hepatocellular Carcinoma.- 5. Chemotherapy of Advanced Colorectal Cancers.- 6. Adjuvant Combined Modality Therapy for Rectal Carcinoma.- 7. Local-Regional Therapy for Metastatic Liver Tumors.- 8. Anal Carcinoma.- 9. Biologic Therapy of Gastrointestinal Cancer.- 10. New Trends in Gastrointestinal Surgical Oncology.- 11. Recent Insights into the Molecular Basis of Intrinsic Resistance of Colorectal Cancer.- 12. Molecular Biology of Pancreatic Cancer.- 13. The Molecular Genetics of Colonic Cancer.

' ...a well-edited book such as this, with contributions from recognized leaders in the field, fills an especially important niche when the results of every clinical trial are but a few mouse clicks away. It provides a tangible way for clinicians who are inundated with information to gain perspective on the relative importance of research studies and to find out how and why some therapies have become standard whereas others have remained controversial.'Deborah Schrag in The New England Journal of Medicine, 341:16 (1999)'...For these reasons, it can be recommended to both an audience of general oncologists and specialists in the field.'P. Saletti in Annals of Oncology, 10: (1999)